desipramine has been researched along with Colonic Diseases, Functional in 8 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Colonic Diseases, Functional: Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD)." | 5.10 | Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. ( Akman, D; Bangdiwala, SI; Blackman, CJ; Bradshaw, B; Dalton, CB; Diamant, NE; Drossman, DA; Duncan, S; Emmott, S; Frusciante, K; Hu, Y; Jia, H; Koch, GG; Le, T; Li, JZ; Meyer, K; Mikula, K; Morris, CB; Proffitt, V; Toner, BB; Whitehead, WE, 2003) |
| " Within psychiatry, when using higher dosage of TCAs, plasma levels can be used to adjust daily dosage to optimize a treatment response." | 1.33 | Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. ( Bangdiwala, SI; Dalton, CB; Diamant, NE; Drossman, DA; Halpert, A; Hu, Y; Morris, CB; Toner, BB; Whitehead, WE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinland, SR | 1 |
| Morris, CB | 4 |
| Dalton, C | 1 |
| Hu, Y | 5 |
| Whitehead, WE | 5 |
| Toner, BB | 5 |
| Diamant, N | 2 |
| Leserman, J | 2 |
| Bangdiwala, SI | 5 |
| Drossman, DA | 4 |
| Diamant, NE | 3 |
| Dalton, CB | 3 |
| Duncan, S | 1 |
| Emmott, S | 1 |
| Proffitt, V | 1 |
| Akman, D | 1 |
| Frusciante, K | 1 |
| Le, T | 1 |
| Meyer, K | 1 |
| Bradshaw, B | 1 |
| Mikula, K | 1 |
| Blackman, CJ | 1 |
| Jia, H | 2 |
| Li, JZ | 1 |
| Koch, GG | 1 |
| Halpert, A | 1 |
| Drossman, D | 1 |
| Patrick, DL | 2 |
| Greenbaum, DS | 2 |
| Dinan, TG | 1 |
| Barry, S | 1 |
| Ahkion, S | 1 |
| Chua, A | 1 |
| Keeling, PW | 1 |
| Mayle, JE | 1 |
| Vanegeren, LE | 1 |
| Jerome, JA | 1 |
| Mayor, JW | 1 |
| Greenbaum, RB | 1 |
| Matson, RW | 1 |
| Stein, GE | 1 |
| Dean, HA | 1 |
| Halvorsen, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Crossover Trial of Gluten and Gluten With Amylase-trypsin Inhibitors as Triggers of Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome[NCT03664531] | 34 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for desipramine and Colonic Diseases, Functional
| Article | Year |
|---|---|
Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Cognition; Cognitive Beha | 2010 |
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.
Topics: Adult; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Colonic Diseases, Functional; | 2003 |
Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Cognitive Behavioral Therapy; Colonic Diseases, Functional; Des | 2007 |
Preliminary report on antidepressant treatment of irritable bowel syndrome: comments on comparison with anxiolytic therapy.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Atropine; Clinical Trials as Topic | 1984 |
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.
Topics: Adult; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Colonic Diseases, Functional; | 2000 |
Effects of desipramine on irritable bowel syndrome compared with atropine and placebo.
Topics: Adult; Aged; Atropine; Clinical Trials as Topic; Colon, Sigmoid; Colonic Diseases, Functional; Desip | 1987 |
2 other studies available for desipramine and Colonic Diseases, Functional
| Article | Year |
|---|---|
Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Colonic Diseases, F | 2005 |
Assessment of central noradrenergic functioning in irritable bowel syndrome using a neuroendocrine challenge test.
Topics: Adult; Colonic Diseases, Functional; Desipramine; Female; Gastrointestinal Motility; Growth Hormone; | 1990 |